Stock LLY ELI LILLY AND COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Eli Lilly and Company Deutsche Boerse AG

Equities

LLY

US5324571083

Market Closed - Deutsche Boerse AG
Other stock markets
 16:09:30 16/05/2024 BST 		5-day change 1st Jan Change
714.2 EUR -0.78% Intraday chart for Eli Lilly and Company -1.14% +35.65%
05-16 Health Care Flat as Momentum Wanes -- Health Care Roundup DJ
05-16 Eli Lilly: research collaboration with Totus Medicines CF

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 57.68 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+35.65% 694B -
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.77% 593B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.60% 371B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.07% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+6.04% 290B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.77% 239B
B+
NOVARTIS AG Stock Novartis AG
+9.13% 209B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-3.97% 209B
A+
AMGEN INC. Stock Amgen Inc.
+9.27% 169B
C+
PFIZER, INC. Stock Pfizer, Inc.
+0.45% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. LLY Stock
  5. Ratings Eli Lilly and Company